| Zacks Company Profile for Provectus Biopharmaceuticals, Inc. (PVCT : OTC) |
|
|
| |
| • Company Description |
| Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. The company's product portfolio consists of PV-10 Melanoma, PH-10 Psoriasis, PH-10 Atopic Dermatitis, PV-10 Breast Cancer, PV-10 Liver Metastasis and PV-10 Mechanism of Action which are in clinical trials. Provectus Biopharmaceuticals Inc., formerly known as Provectus Pharmaceuticals, Inc., is based in Knoxville, Tennessee.
Number of Employees: 6 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $0.08 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 152,537 shares |
| Shares Outstanding: 420.28 (millions) |
| Market Capitalization: $32.15 (millions) |
| Beta: 0.75 |
| 52 Week High: $0.15 |
| 52 Week Low: $0.05 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
0.26% |
-3.49% |
| 12 Week |
-21.05% |
-33.60% |
| Year To Date |
-36.30% |
-40.35% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Ed Pershing - CEO and Director and Chairman of the Board
Dominic Rodrigues - President and Director; Vice Chairman of the Board
Heather Raines - Chief Financial Officer
Webster Bailey - Director
John W. Lacey, III - Director
|
|
Peer Information
Provectus Biopharmaceuticals, Inc. (CORR.)
Provectus Biopharmaceuticals, Inc. (RSPI)
Provectus Biopharmaceuticals, Inc. (CGXP)
Provectus Biopharmaceuticals, Inc. (BGEN)
Provectus Biopharmaceuticals, Inc. (GTBP)
Provectus Biopharmaceuticals, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 74373P108
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
|
|
Share - Related Items
Shares Outstanding: 420.28
Most Recent Split Date: (:1)
Beta: 0.75
Market Capitalization: $32.15 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/12/25 |
|
|
|
| |
